Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging- Sep 25, 2019Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women
- Sep 16, 2019- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin- Two world leaders in diabetes work together to drive meaningful change in care
- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Aug 26, 2019- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it- Abbott's diagnostic test, currently in development, is poised to be the first point-of-care blood test for assessing concussions on its next generation i-STAT™ device, providing doctors results in 15 minutes
- Aug 14, 2019- Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers- Collaboration is a major step in keeping roads safer as recreational marijuana legalization accelerates[1]
- Jul 15, 2019- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair- G4 includes new clip sizes and an enhanced leaflet grasping feature
- May 21, 2019- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR- Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation at 30 days- Study builds upon Abbott's success with its proven MitraClip™ clip-based technology in treating a similar disease on the left side of the heart
- May 14, 2019- Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies- The BRAIN Initiative brings together the brightest minds across disciplines to improve the treatment and prevention of brain disorders
- Apr 29, 2019- Research found Abbott's High-Sensitive Troponin-I blood test may identify adults at risk of having a cardiac event, independent of other heart disease risk factors- Abbott's core laboratory diagnostic test is the first troponin blood test with CE Mark that can more accurately predict risk of developing heart disease, when added to other heart disease risk assessments, than using other assessments alone